Twist Bioscience (NASDAQ:TWST) SVP Sells $25,410.12 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the sale, the senior vice president directly owned 120,414 shares of the company’s stock, valued at $10,514,550.48. This trade represents a 0.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Trading Up 3.3%

Twist Bioscience stock opened at $99.84 on Friday. The company’s fifty day simple moving average is $67.01 and its 200-day simple moving average is $51.44. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $104.23. The stock has a market cap of $6.22 billion, a P/E ratio of -75.07 and a beta of 2.23.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The company had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same period last year, the company posted ($0.66) earnings per share. The company’s revenue was up 19.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.02 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on TWST shares. Guggenheim upped their target price on Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Leerink Partners set a $80.00 price target on Twist Bioscience in a report on Friday, May 22nd. UBS Group set a $89.00 price target on Twist Bioscience in a research note on Monday, June 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday. Finally, Piper Sandler began coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They set an “overweight” rating and a $85.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $74.60.

Institutional Trading of Twist Bioscience

Several large investors have recently made changes to their positions in the stock. William Blair Investment Management LLC increased its holdings in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after acquiring an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. raised its stake in shares of Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after acquiring an additional 1,696,377 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in Twist Bioscience by 26.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock worth $180,403,000 after purchasing an additional 1,349,867 shares during the last quarter. Millennium Management LLC lifted its holdings in Twist Bioscience by 151.5% in the 3rd quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after purchasing an additional 1,080,722 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after purchasing an additional 832,687 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.